Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Low-Dose Tocilizumab for Acute Chest Syndrome in Sickle Cell Disease

NCT05640271 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT05640271
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05640271 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Low-Dose Tocilizumab for Acute Chest Syndrome in Sickle Cell Disease
Lead sponsor
University of Chicago
Phase
Phase 2
Overall status
Recruiting
Start date
April 10, 2023
Completion date
June 30, 2027
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute chest syndrome, sickle cell disease